January 27, 2015 updated
Updated January 27, 2015
AAAHC Invites You To Download Our Free Medical Home White Paper
Introducing PrevenTips - a series of short videos featuring Dr. Brian Nový!
Oncotype DX® Predicts Outcomes in Prostate Cancer Patients, Significantly Changes Treatment Recommendations
We are pleased to announce FDA approval of Jakafi® (ruxolitinib) for treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea (HU). This new indication makes Jakafi the first and only FDA-approved treatment for these patients.
The Florida Association of Health Plans' mission is to better the health of Florida's citizens by promoting the growth of health plans dedicated to providing the best service, highest quality of care, best value and affordability, and access to their members and business partners. We do this by: